ALTITUDE-AD: Recruitment strategies for a global phase 2 trial of sabirnetug in early Alzheimer&#39;s disease

sabirnetug IV (ACU193 IV) - Acumen Pharma

Robyn MOXON 1; Alyssa CARROLL 1; Todd FEASTER 1; Kathy MARCOZZI PIERCE 1; Maddelyn HYLAND 1; Siew TIN GAN 1; Dung TRINH 2; Eric SIEMERS 1

Dec 14, 2025